They do plenty of investor conferences. They really didn't need it. We seem to have survived that Seeking Alpha article. Although they went into vivid detail on everything that could go wrong, they did also think that getting approval of the drug was very, very high. We really need some news on someone stepping in and doing a new Lupron drug, since the patents are expiring. Something needs to force Abbv's hand into going strong with Elagolix.